WEBSITE BSE:524663 NSE: BH.IMMUN&BIO Inc. Year: 1989 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 11:14
No Notes Added Yet
Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) is a public sector undertaking of the Government of India, established in 1989 in Bulandshahar, Uttar Pradesh. BIBCOL is in manufacturing oral polio vaccines (OPVs) and other immunizers. Saving lives of millions of children from avoidable disability through vaccination, BIBCOL has played a crucial role in the eradication of Poliomyelitis in India. Produces a range of pharmaceutical products, including Zinc Tablets and Diarrhea Management Kits. BIBCOL’s achievements include ...Read More
Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) is a public sector undertaking of the Government of India, established in 1989 in Bulandshahar, Uttar Pradesh. BIBCOL is in manufacturing oral polio vaccines (OPVs) and other immunizers. Saving lives of millions of children from avoidable disability through vaccination, BIBCOL has played a crucial role in the eradication of Poliomyelitis in India. Produces a range of pharmaceutical products, including Zinc Tablets and Diarrhea Management Kits. BIBCOL’s achievements include capturing 60% of the total market share in India for polio vaccines and being recognized as one of the top 20 Biotech companies in India. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹75 Cr.
Stock P/E -4.5
P/B -
Current Price ₹17.3
Book Value ₹ 0
Face Value 10
52W High ₹28.8
Dividend Yield 0%
52W Low ₹ 14.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 25 | 25 | 14 | 25 | 17 | 10 | 26 | 0 | 0 | 0 |
| Other Income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 25 | 26 | 14 | 25 | 18 | 11 | 27 | 0 | 0 | 0 |
| Total Expenditure | 30 | 27 | 13 | 28 | 16 | 15 | 29 | 5 | 4 | 5 |
| Operating Profit | -4 | -1 | 1 | -3 | 1 | -5 | -2 | -5 | -4 | -5 |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -6 | -2 | 0 | -5 | -0 | -6 | -4 | -6 | -6 | -7 |
| Provision for Tax | -2 | -1 | -2 | 5 | -0 | -1 | -1 | -2 | -1 | -2 |
| Profit After Tax | -4 | -2 | 2 | -9 | -0 | -5 | -3 | -5 | -5 | -5 |
| Adjustments | 0 | -0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | -0 |
| Profit After Adjustments | -4 | -2 | 2 | -9 | -0 | -5 | -3 | -5 | -5 | -5 |
| Adjusted Earnings Per Share | -0.9 | -0.4 | 0.4 | -2.2 | -0.1 | -1.2 | -0.7 | -1.1 | -1.1 | -1.1 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 173 | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 26 |
| Other Income | 1 | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 1 | 0 |
| Total Income | 174 | 209 | 147 | 129 | 125 | 36 | 88 | 68 | 87 | 79 | 46 | 27 |
| Total Expenditure | 164 | 191 | 143 | 132 | 111 | 43 | 93 | 77 | 106 | 83 | 61 | 43 |
| Operating Profit | 10 | 18 | 4 | -3 | 14 | -7 | -5 | -9 | -19 | -4 | -15 | -16 |
| Interest | 2 | 6 | 1 | 6 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 7 | 11 | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -22 | -23 |
| Provision for Tax | 2 | 5 | 1 | -3 | 3 | -4 | -2 | -4 | -6 | -1 | -6 | -6 |
| Profit After Tax | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| Adjusted Earnings Per Share | 1.2 | 1.5 | 0.4 | -1.4 | 1.5 | -1 | -1.3 | -2.4 | -4.2 | -2 | -3.9 | -4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -42% | -12% | 5% | -13% |
| Operating Profit CAGR | 0% | 0% | 0% | NAN% |
| PAT CAGR | 0% | 0% | 0% | NAN% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -22% | -10% | -19% | -1% |
| ROE Average | 0% | -53% | -43% | -17% |
| ROCE Average | -26% | -36% | -28% | -5% |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 42 | 40 | 41 | 35 | 42 | 37 | 31 | 20 | 34 | 105 | 88 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -2 | 3 | 4 | 1 | -1 | -5 | -4 | -8 | -14 | -15 | -20 |
| Total Current Liabilities | 45 | 48 | 35 | 30 | 14 | 13 | 88 | 101 | 64 | 101 | 94 |
| Total Liabilities | 85 | 91 | 80 | 66 | 55 | 45 | 115 | 113 | 84 | 192 | 162 |
| Fixed Assets | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 116 | 116 |
| Other Non-Current Assets | 0 | 1 | 1 | 1 | 3 | 2 | 12 | 15 | 46 | 10 | 10 |
| Total Current Assets | 77 | 84 | 74 | 60 | 47 | 38 | 99 | 93 | 34 | 65 | 36 |
| Total Assets | 85 | 91 | 80 | 66 | 55 | 45 | 115 | 113 | 84 | 192 | 162 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 10 | 41 | 23 | 30 | 20 | 0 | 1 | 0 | 1 | 1 | 5 |
| Cash Flow from Operating Activities | 31 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Cash Flow from Financing Activities | -0 | -6 | -1 | -2 | -3 | -3 | 31 | -34 | -12 | 45 | -15 |
| Net Cash Inflow / Outflow | 31 | -18 | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | -3 |
| Closing Cash & Cash Equivalent | 41 | 23 | 30 | 20 | 0 | 1 | 0 | 1 | 1 | 5 | 1 |
| # | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.16 | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.85 |
| CEPS(Rs) | 1.45 | 1.72 | 0.57 | -1.29 | 1.64 | -0.89 | -1.28 | -2.31 | -4.14 | -1.98 | -3.81 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 9.72 | 9.21 | 9.57 | 8.13 | 9.67 | 8.68 | 7.1 | 4.74 | 0.55 | -1.48 | -5.33 |
| Core EBITDA Margin(%) | 5.34 | 5.89 | 2.33 | -3.15 | 10.33 | -22.78 | -11.14 | -15.56 | -24.45 | -6.34 | -36.02 |
| EBIT Margin(%) | 5.24 | 8.4 | 2.2 | -2.56 | 10.81 | -19.97 | -6.42 | -14.14 | -22.76 | -5.21 | -34.09 |
| Pre Tax Margin(%) | 3.97 | 5.42 | 1.43 | -7 | 7.43 | -22.87 | -8.82 | -21.25 | -28.37 | -12.36 | -49.92 |
| PAT Margin (%) | 2.9 | 3.16 | 1.06 | -4.85 | 5.24 | -12.25 | -6.93 | -15.28 | -21.23 | -11.17 | -37.3 |
| Cash Profit Margin (%) | 3.63 | 3.67 | 1.68 | -4.34 | 5.71 | -11.06 | -6.6 | -14.92 | -20.95 | -10.9 | -36.85 |
| ROA(%) | 6.31 | 7.28 | 1.81 | -8.5 | 10.8 | -8.51 | -7.22 | -8.97 | -18.41 | -6.35 | -9.41 |
| ROE(%) | 14.27 | 15.68 | 3.81 | -16.25 | 16.94 | -10.76 | -17 | -39.93 | -158.64 | 0 | 0 |
| ROCE(%) | 23.51 | 42.29 | 9.07 | -8.52 | 31.11 | -17.52 | -10.7 | -21.87 | -73.05 | -8.08 | -25.63 |
| Receivable days | 29.17 | 24.53 | 49.8 | 38.16 | 28.7 | 117.47 | 194 | 247.35 | 37.69 | 2.66 | 61.4 |
| Inventory Days | 54.73 | 55.72 | 69.3 | 68.59 | 33.57 | 10.98 | 35.26 | 180.65 | 139.46 | 115.8 | 154.12 |
| Payable days | 84.66 | 81.36 | 103.96 | 66.86 | 16.24 | 4.77 | 115.09 | 286.05 | 131.08 | 47.94 | 8.9 |
| PER(x) | 10.45 | 5.86 | 101.68 | 0 | 14.99 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 1.25 | 0.94 | 3.8 | 2.27 | 2.34 | 2.27 | 1.08 | 1.23 | 83.21 | -18.98 | -4.16 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.06 | 0.06 | 0.81 | 0.54 | 0.47 | 1.87 | 0.69 | 0.24 | 2.5 | 2.38 | 3.53 |
| EV/Core EBITDA(x) | 1.07 | 0.72 | 28.54 | -26.16 | 4.18 | -9.96 | -11.29 | -1.74 | -11.12 | -48.1 | -10.48 |
| Net Sales Growth(%) | 272.88 | 17.34 | -27.88 | -12.44 | -3.01 | -71.98 | 140.37 | -20.1 | 27.68 | -8.14 | -43.09 |
| EBIT Growth(%) | 42.33 | 87.88 | -81.08 | -201.79 | 509.23 | -151.74 | 22.72 | -76.01 | -105.48 | 78.97 | -272.4 |
| PAT Growth(%) | -60.08 | 27.74 | -75.87 | -501.65 | 204.85 | -165.46 | -35.93 | -76.27 | -77.38 | 51.67 | -90.08 |
| EPS Growth(%) | -60.08 | 27.74 | -75.87 | -501.66 | 204.85 | -165.46 | -35.93 | -76.27 | -77.38 | 51.67 | -90.08 |
| Debt/Equity(x) | 0 | -0.03 | -0.21 | 0.27 | 0 | 0 | 1.05 | 0.15 | 11.56 | -12.18 | -3.05 |
| Current Ratio(x) | 1.71 | 1.73 | 2.08 | 2 | 3.31 | 3.05 | 1.12 | 0.92 | 0.53 | 0.65 | 0.38 |
| Quick Ratio(x) | 0.99 | 1.11 | 1.36 | 1.25 | 3.28 | 2.91 | 0.95 | 0.41 | 0.32 | 0.29 | 0.37 |
| Interest Cover(x) | 4.13 | 2.83 | 2.85 | -0.58 | 3.19 | -6.88 | -2.68 | -1.99 | -4.06 | -0.73 | -2.15 |
| Total Debt/Mcap(x) | 0 | -0.03 | -0.06 | 0.12 | 0 | 0 | 0.97 | 0.12 | 0.14 | 0.64 | 0.73 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 | 59.25 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 40.75 | 40.75 | 40.75 | 40.75 | 40.75 | 40.75 | 40.75 | 40.75 | 40.75 | 40.75 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.32 | 4.32 | 4.32 | 4.32 | 4.32 | 4.32 | 4.32 | 4.32 | 4.32 | 4.32 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
